Impact of P53 and SIRT1 in Type 2 Diabetes

Summary

Investigating the impact of p53 and SIRT1 in the development of type 2 DM

Eligibility

Inclusion Criteria:

* Prediabetic subjects.

Exclusion Criteria:

* Confirmed diabetes.
* Hepatic or renal impairment.

Conditions2

Interventions2

Related trials

• A Phase I Double Blind Study of Metformin Acting on Endogenous Neural Progenitor Cells in Children and Young Adults With Multiple Sclerosis — The Hospital for Sick Children
• A Phase IV Clinical Trial to Compare the Efficacy and Safety of Metformin+Sodium-Glucose Cotransporter 2 Inhibitor(SGLT2-i)+Thiazolidinedione (TZD) in Patients With Type 2 Diabetes — Boryung Pharmaceutical Co., Ltd
• Acupuncture or Metformin for Insulin Resistance in Women With PCOS — Karolinska Institutet
• Acute Portal Pressure Reduction by Metformin and Carvedilol Compared to Carvedilol Alone in Cirrhosis. — Institute of Liver and Biliary Sciences, India
• Anti-atherosclerotic Efficacy of Selected Antidiabetic Drugs in Patients With Coronary Artery Disease and Pre-diabetes — National Institute of Cardiology, Warsaw, Poland
• Comparative Clinical and Biochemical Study Evaluating the Effectiveness of Metformin Versus Febuxostat on Gouty Obese Non-Diabetic Patients — Mostafa Bahaa
• Effect of Metformin Use on Weight Loss in Obese, Non-diabetic People (MOWRI) — University Of Nigeria Teaching Hospital
• Effect of Tofogliflozin on UACR Compared to Metformin Hydrochloride in Diabetic Kidney Disease (TRUTH-DKD) — Shinshu University

Browse More Trials